Exhibit 2.1 STRICTLY CONFIDENTIAL Proposed Execution Version AGREEMENT AND PLAN OF MERGER by and among ALUMIS INC., ARROW MERGER SUB, INC. and ACELYRIN, INC. Dated as of February 6, 2025 TABLE OF CONTENTS | | | Page | | --- | --- | --- | | | ARTICLE I THE MERGER; CLOSING; SURVIVING CORPORATION | 2 | | 1.1 | The Merger | 2 | | 1.2 | Closing | 2 | | 1.3 | Effective Time | 3 | | 1.4 | Certificate of Incorporation | 3 | | 1.5 | Bylaws | 3 | | 1.6 | Directors of the Surviving Corporation | 3 | | 1.7 | Officers o ...

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical reado ...

Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at ...

LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature ext ...

Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Shephard Mpofu - Chief Medical Officer Conference Call Participants Tyler Van Buren - TD Cowen Emily Bodnar - H.C. Wainwright Vikram Purohit - Morgan Stanley Samantha Semenkow - Citi Operator Good afternoon, and welcome to the Acely ...

Exhibit 99.1 1 ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation of subcutaneous Phase 3 development program in thyroid eye disease (TED) expected in Q1 2025 Cash, cash equivalents, and short-term marketable securities at September 30, 2024 of $562.4 million projected to provide cash ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 | --- | --- | --- | |----------------------------------------------------|------------- ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Acelyrin, Inc. (NASDAQ:SLRN) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Tyler Marciniak - Vice President of Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Shep Mpofu - Chief Medical Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Conference Call Participants Derek Archila - Wells Fargo Tyler Van Buren - TD Cowen Yasmeen Rahimi - Piper Sandler Phoebe Tan - Jefferies Emily Bodnar - H.C. Wainwright Vikram Purohit - ...

| --- | --- | --- | |----------------------------|-------|-------| | | | | | | | | | | | | | | | | | Accelerating Medicines to | | | | Transform Patients' Lives | | | Q2 2024 Financial Results August 13, 2024 Forward Looking Statements & Disclaimer This presentation contains statements that are not of historical facts, considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward- ...